Douglas Liva, MD
Ophthalmology · Paramus, NJNPI 1255447371
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (29.9%), consulting fees and gifts — rather than concentrated in one kind of arrangement. Carl Zeiss Meditec, Inc. accounts for 79.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $6,794 and has fallen 88.5% since, to $782 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $163.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$14K
- Alcon$1K
- Tarsus Pharmaceuticals, Inc.$373
- Johnson & Johnson Surgical Vision, Inc.$367
- AbbVie$360
- Bausch & Lomb Americas Inc.$182
- plus $1K from 14 others
What the payments were for
- Consulting fees$4,76027%
- Speaking & faculty fees$5,28030%
- Travel & lodging$120%
- Food & beverage$3,43519%
- Gifts$3,70721%
- Other$4513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 7 | $14,061 |
| Alcon | 28 | $1,291 |
| Tarsus Pharmaceuticals, Inc. | 8 | $373 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $367 |
| AbbVie(2 entities) | 12 | $360 |
| Bausch & Lomb Americas Inc. | 6 | $182 |
| Aesculap, Inc. | 1 | $175 |
| Aerie Pharmaceuticals, Inc. | 4 | $167 |
| Sun Pharmaceutical Industries Inc. | 8 | $115 |
| Johnson & Johnson Vision Care, Inc. | 5 | $102 |
| Oyster Point Pharma, Inc. | 6 | $101 |
| Amgen | 4 | $68 |
| Novartis | 4 | $57 |
| Astellas Pharma US Inc | 3 | $53 |
| Sight Sciences, Inc. | 2 | $46 |
| NEW World Medical,inc. | 1 | $37 |
| Kala Pharmaceuticals, Inc. | 2 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $27 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humphrey HFA$6,768
- CIRRUS HD-OCT$6,160
- IOLMaster 700$6,160
- Clareon$378
- Humphrey HFA 3$276
- XDEMVY$264
- PanOptix$248
- Tecnis IOL$146
- Catalys Laser System$125
- Tecnis Multifocal Family of 1-piece IOLS$125
- Rhopressa$124
- Rocklatan$124
- AcrySof IQ PanOptix UV IOL$121
- AcrySof IQ VIVITY$121
- RESTASIS$120
- LUMIGAN$114
- MIEBO$114
- XIIDRA$114
- Clareon PanOptix Pro$106
How this compares
$17,645 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 81 | $31,420 |
| RestasisCyclosporine | 39 | $27,258 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $16,989 |
| Cyclosporine | 18 | $13,417 |
| RhopressaNetarsudil Mesylate | 27 | $11,425 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $8,417 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 62 | $7,138 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $5,532 |
| TafluprostTafluprost/Pf | 19 | $5,292 |
| Timolol Maleate | 133 | $3,333 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 14 | $2,290 |
| Bromfenac Sodium | 13 | $2,242 |
| Latanoprost | 302 | $1,761 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 79 | $1,321 |
| Pilocarpine Hcl | 20 | $1,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $360 | $75,667169 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $167 | $19,84252 claims |
| AlconSimbrinza | $1,291 | $5,53226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Paramus
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.